Research output per year
Research output per year
Personal profile
Research interests
I am interested in the development of new agents and treatment approaches for patients with myelodysplastic syndromes and acute myeloid leukemia. In conjunction with Drs. John DiPersio and Michael Rettig, we are currently conducting a Phase I/II Study of AMD3100 (plerixafor) in combination with mitoxantrone, etoposide and cytarabine for relapsed or refractory AML. AMD3100 is a CXCR4 antagonist currently under clinical development as a stem cell mobilizing agent for use in hematopoietic transplantation. Preclinical evidence suggests that AMD3100 can disrupt the interaction of leukemic blasts with the bone marrow microenvironment sensitizing these cells to genotoxic stresses such as chemotherapy. This trial is designed as a proof of concept study to determine if AMD3100 "priming" can improve response rates in AML.
Clinical interests
Bone marrow transplant, oncology, cancer, lymphoma, leukemia, aplastic anemia
Fingerprint
Dive into the research topics where Geoffrey Uy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
Appelbaum, J. S., Wei, A. H., Mandrekar, S. J., Tiong, I. S., Chua, C. C., Teh, T. C., Fong, C. Y., Ting, S. B., Weber, D., Benner, A., Hill, H., Saadati, M., Yin, J., Stone, R. M., Garcia-Manero, G., Erba, H. P., Uy, G. L., Marcucci, G., Larson, R. A. & Thomas, A. & 9 others, , Feb 2024, In: Leukemia. 38, 2, p. 389-392 4 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action
Bhatt, V. R., Uy, G. L. & Klepin, H. D., Feb 8 2024, In: Blood. 143, 6, p. 483-487 5 p.Research output: Contribution to journal › Comment/debate
4 Scopus citations -
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Woyach, J. A., Perez Burbano, G., Ruppert, A. S., Miller, C., Heerema, N. A., Zhao, W., Wall, A., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., Parikh, S. A., Stephens, D. M., Brown, J. R., Lozanski, G., Blachly, J., Nattam, S., Larson, R. A. & Erba, H. & 12 others, , Apr 18 2024, In: Blood. 143, 16, p. 1616-1627 12 p.Research output: Contribution to journal › Article › peer-review
6 Scopus citations -
Gilteritinib as Post-Transplant Maintenance for AML with Internal Tandem Duplication Mutation of FLT3
Levis, M. J., Hamadani, M., Logan, B., Jones, R. J., Singh, A. K., Litzow, M., Wingard, J. R., Papadopoulos, E. B., Perl, A. E., Soiffer, R. J., Ustun, C., Ueda Oshima, M., Uy, G. L., Waller, E. K., Vasu, S., Solh, M., Mishra, A., Muffly, L., Kim, H. J. & Mikesch, J. H. & 19 others, , May 20 2024, In: Journal of Clinical Oncology. 42, 15, p. 1766-1775 10 p.Research output: Contribution to journal › Article › peer-review
Open Access17 Scopus citations -
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model
Archer, K. J., Fu, H., Mrózek, K., Nicolet, D., Mims, A. S., Uy, G. L., Stock, W., Byrd, J. C., Hiddemann, W., Braess, J., Spiekermann, K., Metzeler, K. H., Herold, T. & Eisfeld, A. K., Dec 2024, In: Journal of Hematology and Oncology. 17, 1, 28.Research output: Contribution to journal › Letter › peer-review
Open Access